Evolva has signed a distribution agreement with Lehvoss Group Nutrition Division for the distribution of Evolva’s Veri-te Resveratrol for use in dietary supplements across Europe.
Image courtesy of Lehvoss Group.
Evolva (Reinach, Switzerland) has signed a distribution agreement with Lehvoss Group Nutrition Division (Congleton, Cheshire, UK) for the distribution of Evolva’s Veri-te Resveratrol for use in dietary supplements. Veri-te will be distributed across Europe, and with over a dozen European countries covered under the agreement, Lehvoss anticipates that the distribution agreement will generate approximately CHF 1.5 million in sale by the end of 2025.
“We are very excited to strengthen the presence of our Veri-te Resveratrol across a wider range of European countries,” said Anne De Vos, chief commercial officer of Evolve, in a press release. “Veri-te Resveratrol is a responsible multi-functional ingredient with proven health benefits supported by a number of clinical studies. We consider Lehvoss to be an ideal partner for the distribution of Veri-te™ Resveratrol due to its exceptional market capabilities.”
“We are thrilled to add this high quality, researched and sustainable brand to our portfolio,” said Teresita Rudà, head of Brands and Marketing for Lehvoss Nutrition. “We are convinced that Veri-te Resveratrol will add strength to our specially selected offer[ings] of ingredients across Europe and we look forward to a successful partnership with Evolva.”
Roquette completes acquisition of IFF Pharma Solutions
May 1st 2025The integration of IFF Pharma Solution’s expertise and innovative product portfolio enhances Roquette’s “ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide while reinforcing its commitment to innovation,” according to the company’s press release.